MEXA-CTP: Mode Experts Cross-Attention for Clinical Trial Outcome Prediction

• URL: http://arxiv.org/abs/2501.06823v1
• Date: Sun, 12 Jan 2025 14:35:31 GMT
• Title: MEXA-CTP: Mode Experts Cross-Attention for Clinical Trial Outcome Prediction
• Authors: Yiqing Zhang, Xiaozhong Liu, Fabricio Murai,
• Abstract summary: We propose a light-weight attention-based model, MEXA-CTP, to integrate readily-available multi-modal data and generate effective representations. Our experiments on the Trial Outcome Prediction benchmark demonstrate that MEXA-CTP improves upon existing approaches by up to 11.3% in F1 score, 12.2% in PR-AUC, and 2.5% in ROC-AUC.
• Score: 14.116060944536011
• License:
• Abstract: Clinical trials are the gold standard for assessing the effectiveness and safety of drugs for treating diseases. Given the vast design space of drug molecules, elevated financial cost, and multi-year timeline of these trials, research on clinical trial outcome prediction has gained immense traction. Accurate predictions must leverage data of diverse modes such as drug molecules, target diseases, and eligibility criteria to infer successes and failures. Previous Deep Learning approaches for this task, such as HINT, often require wet lab data from synthesized molecules and/or rely on prior knowledge to encode interactions as part of the model architecture. To address these limitations, we propose a light-weight attention-based model, MEXA-CTP, to integrate readily-available multi-modal data and generate effective representations via specialized modules dubbed "mode experts", while avoiding human biases in model design. We optimize MEXA-CTP with the Cauchy loss to capture relevant interactions across modes. Our experiments on the Trial Outcome Prediction (TOP) benchmark demonstrate that MEXA-CTP improves upon existing approaches by, respectively, up to 11.3% in F1 score, 12.2% in PR-AUC, and 2.5% in ROC-AUC, compared to HINT. Ablation studies are provided to quantify the effectiveness of each component in our proposed method.

Related papers

• TrialBench: Multi-Modal Artificial Intelligence-Ready Clinical Trial Datasets [57.067409211231244]
  This paper presents meticulously curated AIready datasets covering multi-modal data (e.g., drug molecule, disease code, text, categorical/numerical features) and 8 crucial prediction challenges in clinical trial design. We provide basic validation methods for each task to ensure the datasets' usability and reliability. We anticipate that the availability of such open-access datasets will catalyze the development of advanced AI approaches for clinical trial design.
  arXiv  Detail & Related papers  (2024-06-30T09:13:10Z)
• TrialDura: Hierarchical Attention Transformer for Interpretable Clinical Trial Duration Prediction [19.084936647082632]
  We propose TrialDura, a machine learning-based method that estimates the duration of clinical trials using multimodal data. We encode them into Bio-BERT embeddings specifically tuned for biomedical contexts to provide a deeper and more relevant semantic understanding. Our proposed model demonstrated superior performance with a mean absolute error (MAE) of 1.04 years and a root mean square error (RMSE) of 1.39 years compared to the other models.
  arXiv  Detail & Related papers  (2024-04-20T02:12:59Z)
• CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results [0.10051474951635876]
  Adverse drug events (ADEs) significantly impact clinical research, causing many clinical trial failures. To support this effort, we introduce CT-ADE, a dataset for multilabel predictive modeling of ADEs in monopharmacy treatments. CT-ADE integrates data from 2,497 unique drugs, encompassing 168,984 drug-ADE pairs extracted from clinical trials, annotated with patient and contextual information, and comprehensive ADE concepts standardized across multiple levels of the MedDRA.
  arXiv  Detail & Related papers  (2024-04-19T12:04:32Z)
• SECRETS: Subject-Efficient Clinical Randomized Controlled Trials using Synthetic Intervention [0.0]
  Cross-over trials can reduce sample size requirements by measuring the treatment effect per individual. We propose a novel framework, SECRETS, which estimates the individual treatment effect (ITE) per patient in the RCT study without using any external data. We show that SECRETS can improve the power of an RCT while maintaining comparable significance levels.
  arXiv  Detail & Related papers  (2023-05-08T22:37:16Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data [56.53715632642495]
  Clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions.
  arXiv  Detail & Related papers  (2021-02-08T15:09:07Z)
• Predicting Clinical Trial Results by Implicit Evidence Integration [40.80948875051806]
  We introduce a novel Clinical Trial Result Prediction (CTRP) task. In the CTRP framework, a model takes a PICO-formatted clinical trial proposal with its background as input and predicts the result. We exploit large-scale unstructured sentences from medical literature that implicitly contain PICOs and results as evidence.
  arXiv  Detail & Related papers  (2020-10-12T12:25:41Z)
• Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions [80.12620331438052]
  deep learning has become an important tool for rapid screening of billions of molecules in silico for potential hits containing desired chemical features. Despite its importance, substantial challenges persist in training these models, such as severe class imbalance, high decision thresholds, and lack of ground truth labels in some datasets. We argue in favor of directly optimizing the receiver operating characteristic (ROC) in such cases, due to its robustness to class imbalance.
  arXiv  Detail & Related papers  (2020-06-25T08:46:37Z)
• Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints [84.09488581365484]
  Phase I dose-finding trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds becomes more complex. Most commonly used methods in practice focus on identifying a Maximum Tolerated Dose (MTD) by learning only from toxicity events. We present a novel adaptive clinical trial methodology that aims at maximizing the cumulative efficacies while satisfying the toxicity safety constraint with high probability.
  arXiv  Detail & Related papers  (2020-06-09T03:06:45Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.